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Abstract
Introduction: During the course of infection, natural killer (NK) cells contribute to innate immunity by producing
cytokines, particularly interferon-gamma (IFN-g). In addition to their beneficial effects against infection, NK cells may
play a detrimental role during systemic inflammation, causing lethality during sepsis. Little is known on the
immune status of NK cells in patients with systemic inflammatory response syndrome (SIRS) or sepsis in terms of
cell surface markers expression and IFN-g production.
Methods: We investigated 27 sepsis patients and 11 patients with non-infectious SIRS. CD56bright and CD56dim NK
cell subsets were identified by flow cytometry and Toll-like receptor (TLR)2, TLR4, TLR9, CX3CR1, CD16 and CD69
expression were analyzed, as well as ex vivo IFN-g production by NK cells in whole blood samples.
Results: We first showed that in NK cells from healthy controls, TLR2 and TLR4 expression is mainly intracellular,
similarly to TLR9. Intracellular levels of TLR2 and TLR4, in both CD56bright and CD56dim NK cell subsets from sepsis
patients, were increased compared to healthy subjects. In addition, the percentage of CD69+ cells was higher
among NK cells of sepsis patients. No difference was observed for TLR9, CX3CR1, and CD16 expression. The ex vivo
stimulation by TLR4 or TLR9 agonists, or whole bacteria in synergy with accessory cytokines (IL-15+IL-18), resulted
in significant production of IFN-g by NK cells of healthy controls. In contrast, for SIRS and sepsis patients this
response was dramatically reduced.
Conclusions: This study reports for the first time an intracellular expression of TLR2 and TLR4 in human NK cells.
Surface TLR4 expression allows discriminating sepsis and SIRS. Furthermore, during these pathologies, NK cells
undergo an alteration of their immune status characterized by a profound reduction of their capacity to release
IFN-g.
Introduction
Both severe sepsis and systemic inflammatory response
syndrome (SIRS) are characterized by an exacerbated
inflammatory response and a cytokine storm [1]. Conco-
mitantly, sepsis and SIRS patients undergo a compensa-
tory anti-inflammatory response syndrome (CARS) [2].
This modification of immune status, also called repro-
gramming, has been regularly reported for circulating
monocytes, neutrophils and lymphocytes in sepsis [3-5].
This alteration is also characterized by reduced HLA-
DR expression on monocytes [6]. Leukocytes from
septic patients respond poorly to Toll-like receptor
(TLR) agonists compared to cells from healthy subjects
[7-9]. In many aspects, this hypo-reactivity resembles
the well-known phenomenon of endotoxin tolerance,
which is characterized by lack of response to a second
challenge with lipopolysaccharide (LPS) in vivo or in
vitro, given shortly after a first exposure to LPS [7]. The
concept has been extended to all TLR agonists.
Although the immune status of monocytes, lympho-
cytes and neutrophils is well-characterized in SIRS and
sepsis patients, little is known about that of natural
killer (NK) cells in these patients. In humans, at least 2
subsets of circulating NK cells have been described, the
CD3-CD56dim and CD3-CD56bright. These two subsets
do or do not express other cell surface markers (for
example, CCR7, CD25, CD117), and show differential
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function (for example, CD56dim NK cells display
enhanced cytotoxicity; CD56bright NK cells produce
greater amounts of cytokines) [10]. NK cells are a major
source of IFN-g, a cytokine known to activate mono-
cytes and macrophages, and to contribute to immune
responses against bacterial infections [11,12]. However,
experiments performed with recombinant IFN-g, neutra-
lizing antibodies, or IFN-g-receptor-deficient mice,
established that this cytokine is also a key contributor to
lethality after LPS injection or in sepsis models [13-15].
Circulating IFN-g is found after LPS injection in mice
[16] and in murine models of polymicrobial sepsis [17],
as well as in patients with sepsis [18]. In vivo induction
of endotoxin tolerance is associated with a dramatic
reduction of circulating IFN-g [16]. IFN-g is also known
to prevent endotoxin tolerance of monocytes and
macrophages [19], and has been shown to reverse the
altered immune status of monocytes in human sepsis
[20]. Similarly, beneficial and deleterious roles of NK
cells have been reported during bacterial infection, (for
review see [21]). Protective functions of NK cells have
been reported in septic peritonitis and in lung infection
with Gram-positive bacteria. In contrast, deleterious
roles of NK cells have been reported in animal models
after polymicrobial intra-abdominal sepsis, Escherichia
coli intraperitoneal injection, Streptococcus pyogenes
intravenous injection, cytokine-induced SIRS, and in a
polytrauma model.
Little is known about the specific responsiveness of
human NK cells to pathogen-associated molecular pat-
terns (PAMPs), although they do express mRNA encod-
ing for TLRs [22-24]. It has been reported that after
LPS or bacterial DNA challenge, most IFN-g-producing
cells were NK cells [25,26]. Endotoxin (a TLR4 agonist),
flagellin (a TLR5 agonist), and outer membrane protein
A (a TLR2 agonist) alone are each weak stimuli for NK
cells of healthy volunteers, whereas in the presence of
accessory cytokines (for example, IL-2, IL-15, IL-12, or
IL-18) large amounts of IFN-g are produced [23,27].
Similarly, NK cells are able to respond to nucleotide oli-
gomerization domain receptor 2 (NOD2) agonists [28]
or endogenous danger signals such as high-mobility
group, box 1 [29]. However, the capacity of NK cells to
respond to TLR agonists has not yet been characterized
in SIRS and sepsis patients. In sepsis patients, a decrease
in the number of circulating NK cells has been regularly
reported [30,31]. When NK cells were functionally stu-
died, their cytotoxic activity was found to be reduced in
sepsis patients [32,33] and also in SIRS patients follow-
ing thermal and traumatic injury [34,35]. Very few stu-
dies have addressed the capacity of NK cells in sepsis or
SIRS patients to produce IFN-g. Additionally no study
has shown the expression levels of the early activation
marker CD69 [36] on the surface of this cell type in
these patients. It has been shown that the production of
IFN-g in response to IL-2 and IL-12 in combination
(with or without IL-18) is altered in patients who
undergo elective surgery and severely impaired in
patients with sepsis [37]. However, to date, no study has
addressed the responsiveness of NK cells to TLR ago-
nists in human SIRS and sepsis.
This report investigates the modulation of cell surface
markers (activation markers and receptors), and for the
first time, TLR expression on NK cells of SIRS and sep-
sis patients. Furthermore, we investigated the capacity of
NK cells to produce IFN-g in the presence of TLR ago-
nists and stimulatory cytokines, to investigate whether
these cells could exhibit endotoxin tolerance as pre-
viously shown for monocytes. In addition, we extended
our study by analyzing the two NK cell subsets
(CD56bright and CD56dim).
Materials and methods
Patients
Patients included in this study belong to the combined
approach for the early diagnosis of sepsis (CAPTAIN)
cohort (ClinicalTrial, n°NCT01378169) and were from
all seven ICUs involved in this protocol. The CAPTAIN
study is an ongoing observational multicenter investiga-
tion aimed to define the best combination of biomarkers
(plasmatic microbial or host markers; leukocyte surface
markers) for an early diagnostic of sepsis in ICU
patients. All patients receive conventional therapy and
care. The study was approved by the regional ethical
committee on 19 November 2010 (Comité de Protection
des Personnes - Ile de France XI, number: 2010-A00908-
31). Written informed consent to participate in the
study was obtained for each patient, or if impossible,
from the patient’s next-of-kin. Presence of SIRS and sus-
picion of infection were the only criteria for inclusion.
Intensive care patients with SIRS were included within
24 hours after medical staff suspected infection. Practi-
cally, this was when patients had fever associated with
biological parameters (increase in white blood cells, CRP
level) and a suspected infection site. Infection could be
community- or hospital-acquired and the blood sample
could be taken just after ICU admission or at any time
during the ICU stay. Immunocompromised individuals
were excluded (defined as individuals with ongoing can-
cer, hematologic malignancy, bone marrow or peripheral
stem cell transplants, or AIDS), as were individuals
undergoing chemotherapy, immunosuppressive therapy,
or using steroids (> 10 mg a day for more than 15
days). Thirty-eight patients were included in this ancil-
lary study. Individuals in whom infection was confirmed
were classified as sepsis patients. Individuals in whom
infection was not confirmed were classified as SIRS
patients with SIRS of non-infectious origin. Patients
Souza-Fonseca-Guimaraes et al. Critical Care 2012, 16:R206
http://ccforum.com/content/16/5/R206
Page 2 of 14
were compared to ten healthy volunteers (Etablissement
Français du Sang, EFS/Groupe Hospitalier Pitié-
Salpetrière).
Reagents
Labeled antibodies against the following antigens were
used: (VioBlue)-anti-CD3 clone BW264/56, (APC)-anti-
CD16 clone VEP13, (PE)-anti-CD56 clone AF12-7H3
from Miltenyi Biotec (Bergisch-Gladbach, Germany);
(FITC)-anti-CD69 clone FN50 from BD Biosciences
(San Diego, CA, USA); (A647)-anti-CX3CR1 clone 2A9-
1, (A647)-anti-TLR2 clone TL2.1 from Biolegend (San
Diego, CA, USA); (A647)-anti-TLR4 clone 76B357.1 and
(A488)-anti-TLR9 clone 26C593.2 from Imgenex (San
Diego, CA, USA). The IFN-g secretion assay, and the
Inside Stain Kit were purchased from Miltenyi Biotec.
The human recombinant cytokines IL-15 and IL-18
were obtained from Miltenyi Biotec and MBL (Boston,
MA, USA) respectively. The PAMPs used were lipopoly-
saccharide (LPS) TLRgrade from E. coli serotype 0111:
B4 (Alexis, San Diego, CA, USA), hCpG-DNA 5’-
ATAATCGACGTTCAAGAAAG-3’ (Sigma-Gensys, The
Woodlands, TX, USA) and heat-killed S. aureus (HKSA)
(Calbiochem, La Jolla, CA, USA).
Ex vivo culture conditions and IFN-g assays
Because NK cells represent a small percentage of circu-
lating leukocytes, and the volume of blood samples was
limited, the experiments were performed in whole
blood, and IFN-g production by the two CD56bright and
CD56dim NK cell subsets was analyzed by flow cytome-
try. For the IFN-g secretion and CD69 expression assays,
blood samples (125 μL) were diluted 1:1 with RPMI
1640 (LONZA, Rockland, ME, USA) alone (control); or
with RPMI 1640 containing IL-15 and IL-18 (IL-15/IL-
18) at 10 ng/mL final each; or IL-15/IL-18 plus LPS at
100 ng/mL; or IL-15/IL-18 plus CpG-DNA at 1 μM; or
IL-15/IL-18 plus HKSA at 10 μg/mL. Cultures were
primed by incubating overnight (16 h) at 37°C in a 5%
CO2 humidified incubator.
For the CD69 measurements after in vitro cultures,
samples were washed with 5 mL of staining buffer (PBS,
EDTA 2 mM and FCS 0.5%), then stained for CD3,
CD56, CD69 and CX3CR1 as described below. For the
IFN-g secretion assay (Miltenyi Biotec), after overnight
incubation, blood samples were washed with 5 mL of
cold staining buffer then centrifuged at 300 × g for 5
minutes at 4°C. Blood samples were then incubated on
ice for 5 minutes with 5 μL of the IFN-g catch reagent
and 40 μL of ice-cold RPMI 1640 containing 10%
human serum (BioWhittaker, Walkersville, MD, USA).
Then, 5 μL of IFN-g catch reagent and 2.5 mL of warm
(37°C) RPMI 1640 containing 10% human serum were
added to the blood samples; the mixture was agitated at
90 rpm for 2 hours at 37°C (agitation is crucial to avoid
IFN-g capture by non-secreting cells). Finally, samples
were washed with 5 mL of staining buffer and incubated
with (VioBlue)-anti-CD3 and (PE)-anti-CD56 mAbs to
determine NK cell subsets as described in the following
section.
Flow cytometry
NK cell surface antigens were labeled by diluting antibo-
dies in staining buffer at the concentrations suggested
by the manufacturers. All whole blood samples (100 μL)
were immediately processed for multiple staining with 5
μL (VioBlue)-anti-CD3 and 5 μL (PE)-anti-CD56 antibo-
dies to discriminate NK cell subsets (CD3-/CD56bright
and CD3-/CD56dim). The following antibodies were
combined to evaluate the expression of other markers:
5 μL (APC)-anti-CD16, 5 μL (FITC)-anti-CD69, 2 μL
(A647)-anti-CX3CR1, 2 μL (A647)-anti-TLR2, 2 μL
(A647)-anti-TLR4, or 1.5 μL (A488)-anti-TLR9. After 20
minutes incubation in the dark at 4°C, 2 mL of lysis buf-
fer (BD Pharm lyse) was added for at least 10 minutes at
25°C. The incubation was followed by centrifugation
(300 × g for 5 minutes), the cells were washed with 2
mL of staining buffer, centrifuged again and then re-sus-
pended in 500 μL of staining buffer for surface expres-
sion analysis or in fixation buffer for intracellular
staining. Intracellular stain for TLR2, TLR4 and TLR9
was performed after red blood cell lysis, washing, fixa-
tion and permeabilization of the cells using Inside Stain
Kit (Miltenyi Biotec), according to the manufacturer’s
instructions. All flow cytometry data were acquired on a
MACSQuant flow cytometer (Miltenyi Biotec) and ana-
lyzed using the MACSQuantify software. Anti-TLR anti-
bodies were previously tested on monocytes, used as
positive controls (data not shown). For each antibody,
an isotype control with the same fluorophore from the
same manufacturer was used as negative staining con-
trol. The number of NK cells was determined by gating
on CD3-/CD56bright and CD3-/CD56dim subsets using
the MACSQuant cytometer, allowing absolute counting.
Statistical analysis
One-way analysis of variance (ANOVA) and the Tukey
post hoc test were performed for statistical analysis of
flow cytometry data. A P-value < 0.05 was considered
significant.
Results
Patients’ characteristics
Eleven patients were classified as non-infectious SIRS,
and 27 were defined as sepsis patients [38]. Patient char-
acteristics are described in Table 1. Among sepsis
patients, the lung was the primary site of sepsis in
almost two-thirds of the sepsis patients. Twelve patients
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had Gram-positive infections. Eight patients had an iso-
lated Gram-positive infection, three involved a Gram-
positive and a Gram-negative bacterium and one a
Gram-positive bacterium and Mycobacterium tuberculo-
sis. Sixteen patients had Gram-negative infections, with
one (eleven patients) or two (two patients) different bac-
teria or with concomittant Gram-positive infection
(three patients). A total of 19 Gram-negative bacteria
were identified, including Escherichia coli in seven
patients, Klebsiella pneumoniae in four patients, Hemo-
philus influenzae in two patients, and Pseudomonas
aeruginosa in two patients. In terms of Gram-positive
bacteria, Staphylococcus aureus was found in five
patients, Streptococcus spp. in four and Streptococcus
pneumoniae in one patient. Mycobacterium tuberculosis
was found in only one patient as was Candida albicans.
More than one pathogen was found in six patients.
Decrease in the number of CD56bright and CD56dim NK
cells subsets after SIRS
The absolute number of NK cells was analyzed in SIRS
and in sepsis patients within the first 24 hours of
Table 1 Parameters of the studied patients
Parameter SIRS (n = 11) Sepsis (n = 27)
Age, y, mean (SD) 59.7 (21.0) 70.6 (14.9)
Gender, n (%)
Male 10 (90.9%) 14 (51.8%)
Female 1 (9.1%) 13 (48.2%)
Body mass index, Kg/m2, mean (SD) 26.2 (6.2) 26.9 (7.2)
Comorbidity, n (%)
Heart failure 0 (0%) 1 (3.7%)
Ischemic cardiopathy 1 (9.1%) 7 (25.9%)
COPD 3 (27.3%) 4 (14.8%)
Chronic renal failure 1 (9.1%) 3 (11.1%)
Liver failure 0 (0%) 1 (3.7%)
Diabetes 1 (9.1%) 6 (22.2%)
Cancer 2 (18.2%) 5 (18.5%)
Infection site
Lung NA 17 (62.9%)
Abdominal NA 7 (25.9%)
Urinary tract NA 2 (7.4%)
Positive blood culture NA 7 (25.9%) (among these, one had primitive bacteremia)
Temperature, °C, mean (SD) 38.2 (2.0) 37.8 (2.1)
Heart rate, bpm, mean (SD) 127 (23) 121.9 (18.7)
Mean blood pressure, mmHg, mean (SD) 72.9 (19.7) 65.2 (23)
Respiratory rate, c/min, mean (SD) 29.8 (14.4) 30.1 (8.2)
Leukocytes, 10E9/L, mean (SD) 12.9 (4.4) 15.08 (8.4)
SOFA, mean (SD) 8.3 (3.4) 9.1 (4.1)
SAPS II, mean (SD) 41.4 (17.5) 48.3 (21.3)
McCABE classification (underlying diseases)
Category 1, number (%) 10 (90.9%) 22 (81.5%)
Category 2, number (%) 1 (9.1%) 4 (14.8%)
Category 3, number (%) 0 (0%) 1(3.7%)
Length of stay in hospital, days, mean (SD) 30.0 (35.2) 40.2 (42.0)
Length of stay in ICU, days, mean (SD) 11.4 (10.6) 24.1 (33.6)
In-hospital mortality, number (%) 3 (27.3%) 12 (44.4%)
Microbes, number patients Gram-positive bacteria NA 12 (among these two had Gram-positive anaerobes)
Gram-negative bacteria NA 19
Mycobacterium spp. NA 1
Fungus NA 1
Undetermined microbial infection 1 (polymicrobial flora)
COPD, chronic obstructive airways disease; NA, not applicable; SOFA, sequential organ failure assessment; SAPS, simlified acute physiology score; SIRS, systemic
inflammatory response syndrome.
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suspicion of infection. The number of NK cells in each
subset (CD56bright and CD56dim) was compared between
sepsis patients, SIRS patients, and healthy donors. A
representative flow cytometry result for each group is
shown in Figure 1A and the median and interquartile
range of each group are shown in Figure 1B. It is clear
that the number of NK cells in both subsets was signifi-
cantly decreased in the blood of sepsis and SIRS
patients, in comparison to healthy controls. No differ-
ence was found between patients with SIRS of infectious
versus non-infectious etiology. These results parallel the
global lymphopenia observed in ICU patients. When the
Figure 1 Analysis of NK cells CD56bright and CD56dim subsets in sepsis and systemic inflammatory response syndrome (SIRS) patients.
(A) Representative chart of analysis of natural killer (NK) cells in whole blood by flow cytometry. (B) Cell counts for total lymphocytes and NK
cell subsets (CD56bright and CD56dim) in healthy volunteers, SIRS, and sepsis patients. (C) Percent of NK subsets among lymphocytes in healthy
volunteers, SIRS, and sepsis patients. Data are shown as median and interquartile range. **P < 0.01; ***P < 0.001.
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number of NK cells was proportionally expressed as per-
cent of the total lymphocyte population, the percent of
CD56dim NK subset was significantly decreased in both
SIRS and sepsis patients (Figure 1C).
Sepsis and SIRS modify the expression of TLR2 and TLR4
in NK cells
We then analyzed the expression of TLR2 and TLR4 on
and within NK cell subsets. Most of our knowledge
about TLR expression in NK cells relies on mRNA ana-
lysis. Furthermore, both mRNA [22-24] and protein sur-
face expression on human NK cells [39,40] remain
controversial. We found that surface expression of TLR2
was barely detectable on both CD56bright and CD56dim
subsets of NK cells for all groups both in terms of per-
centage of positive cells and mean fluorescence intensity
(MFI) (Figure 2A-B). In contrast, a strong intracellular
expression of TLR2 was detected after cell permeabiliza-
tion in both subsets in healthy donors, as well as in
SIRS and sepsis patients (Figure 2C-D). The percentage
of intracellular TLR2-positive CD56dim NK cells was sig-
nificantly increased in sepsis and SIRS patients com-
pared to healthy controls. Interestingly, the MFI for
TLR2 in both CD56bright and CD56dim was significantly
increased for sepsis patients compared to healthy
volunteers.
For TLR4, similarly to TLR2, surface expression was
extremely low for healthy controls and patients in terms
of MFI (Figure 3A-B). Nevertheless, in comparison to
healthy controls and sepsis patients, SIRS patients
showed an increase in the percentage of surface TLR4-
positive cells for both NK subsets. In keeping with the
trend observed for TLR2, a strong intracellular expres-
sion of TLR4 was noted for all three groups (Figure 3C-
D). We found a significantly higher percentage of intra-
cellular TLR4-positive NK cells in SIRS and sepsis
patients for both CD56bright and CD56dim cells in com-
parison to healthy controls. In terms of MFI, an increase
was again noted for both CD56bright and CD56dim NK
cells of septic patients compared to healthy volunteers.
In contrast to TLR2 and TLR4, no difference was found
in the expression of TLR9, the receptor for CpG-DNA
(Additional file 1), either in terms of percentage of posi-
tive cells or MFI.
Sepsis increases the expression of CD69 on NK cells
We then measured the expression of CD69, an early
marker of activation for various cell types, including NK
cells [41,42]. As shown in Figure 4A-B, while CD69 was
barely expressed on NK cells of healthy volunteers, it
was increased and detected in sepsis and SIRS patients.
Nevertheless, this increase in expression was not statisti-
cally significant for the percent positive cells or for MFI.
In addition, we measured the expression of CX3CR1
and CD16. CX3CR1 is the receptor for the chemokine
fractalkin, and is important for the recruitment of NK
cells, especially the CD56dim subset. This receptor has
been shown to be involved in host defense during bac-
terial sepsis [43]. In addition, a study on human sepsis
reported that CX3CR1 protein expression was decreased
on patients’ monocytes [44]. CD16 is the Fcg receptor
III, and is known to be modulated by viral infections
[45]. Flow cytometry analysis comparing healthy con-
trols, SIRS, and sepsis patients showed no differences in
the expression of CX3CR1 or CD16 for either CD56bright
or CD56dim NK cells subsets (data not shown).
Impaired ex vivo upregulation of CD69 for NK cells from
SIRS and sepsis patients
As mentioned previously, CD69 is not expressed on NK
cells from healthy controls and is only expressed on 25
to 30% of NK cells from SIRS and sepsis patients. CD69
is upregulated upon stimulation, and we wondered if
PAMPs or heat-killed Staphylococcus aureus (HKSA)
would be able to enhance CD69 expression ex vivo. As
shown in Figure 4B, IL-15 in combination with IL-18
induced upregulation of CD69 in all groups. While
there was a more pronounced increase in the percentage
of CD69 positive cells for CD56bright subsets, the
increase in MFI was higher in the CD56dim subsets. The
combination of these cytokines with LPS, CpG-DNA, or
HKSA (Figure 4C-E, respectively) induced an even
stronger expression of CD69 on both subsets for healthy
controls (both percentage of positive cells and MFI).
This was particularly noteworthy for CD56dim. Some
increase was observed for SIRS NK cells in response to
LPS, but in almost all cases (except MFI for CD56dim
for IL-15/IL-18 + CpG-DNA) the expression of CD69
on NK cells from patients remained significantly lower
than levels observed for healthy controls. A similar con-
clusion can be drawn for sepsis patients. Only HKSA in
the presence of IL-15 and IL-18 was able to increase the
percentage of CD69 positive cells for CD56dim subset.
However, in terms of MFI, the expression of CD69 was
again reduced on both NK subsets from patients.
Impaired ex vivo IFN-g production by NK cells in SIRS and
sepsis patients
The reactivity of NK cells to TLR agonists in terms of
cytokine production has never been studied, especially
in terms of IFN-g production. We therefore studied the
capacity of NK cells to produce IFN-g ex vivo after sti-
mulation with PAMPs or HKSA, and the combination
of IL-15 and IL-18, two key cytokines for NK cell
maturation and function. IFN-g production was not
observed for unstimulated blood alone (data not shown),
nor when IL-15 and IL-18 were added in the absence of
microbial activators (Figure 5A). Similarly, when NK
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cells were stimulated with PAMPs or HKSA alone, they
were unable to produce IFN-g (data not shown). Instead,
the presence of IL-15/IL-18 and LPS, CpG-DNA or
HKSA induced high levels of IFN-g secretion by both
subsets of NK cells for healthy controls (Figure 5B-D).
In contrast, when the percentage of positive cells and
MFI were measured in sepsis and SIRS patients, IFN-g
production was severely and significantly impaired (see
Additional file 2 for representative flow cytometry
histograms).
Discussion
The present study aimed to further characterize the
immune status of NK cells in patients with non-infectious
Figure 2 Analysis of the expression of Toll-like receptor 2 (TLR2) by flow cytometry in natural killer (NK) cell CD56bright and CD56dim
subsets. (A) Representative flow cytometry histogram of surface expression of TLR2 on CD56bright and CD56dim NK cell subsets for healthy
volunteers, systemic inflammatory response syndrome (SIRS), and sepsis patients. Black line: isotype control; colored line: anti-TLR2. (B) Surface
TLR2 expression shown as median and interquartile range in all three studied groups. (C) Representative flow cytometry histogram of
intracellular expression of TLR2 for the same samples represented in (A). Black line: isotype control; colored line: anti-TLR2. (D) Intracellular TLR2
expression shown as median and interquartile range in all three studied groups. **P < 0.01 for comparison with healthy controls. MFI, mean
fluorescence intensity.
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SIRS or sepsis. In agreement with previous reports, we
observed that the number of circulating NK cells was sig-
nificantly decreased in SIRS and sepsis patients [30,31].
This decrease is the reflection of a general lymphopenia
and may be due to the trafficking of NK cells to the sites
of infection [46], or to apoptosis [47]. Interestingly, some
reports suggest that NK cell percentages or counts are
associated with outcome [48]. Our work further estab-
lishes that the decrease is similarly observed for both
CD56bright and CD56dim NK cells subsets.
We characterized NK cells for the surface biomarkers
CX3CR1 (fractalkine receptor), CD16 (FcgRIII), and
Figure 3 Flow cytometry analysis of Toll-like receptor 4 (TLR4) expression in natural killer (NK) cell CD56bright and CD56dim subsets. (A)
Representative flow cytometry histogram of surface expression of TLR4 on CD56bright and CD56dim NK cell subsets for healthy volunteers,
systemic inflammatory response syndrome (SIRS), and sepsis patients. Black line: isotype control; colored line: anti-TLR4. (B) Surface TLR4
expression shown as median and interquartile range in all three studied groups. (C) Representative flow cytometry histogram of intracellular
expression of TLR4 for the same samples represented in (A). Black line: isotype control; colored line: anti-TLR4. (D) Intracellular TLR4 expression
shown as median and interquartile range in all three groups. *P < 0.05; **P < 0.01; ***P < 0.001 for comparison with healthy donors. #P < 0.05
for SIRS versus sepsis patients. MFI, mean fluorescence intensity.
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CD69. While there was no significant modification of
CX3CR1 and CD16 expression, we found a trend for an
enhanced expression of the early activation marker CD69
in vivo after sepsis. However, as TLRs and CD69 stain-
ings were not performed in the same tubes, we cannot
compare TLR2 and TLR4 expression on CD69- and
CD69+ NK cells. CD69 is upregulated upon activation by
cytokines, TLR agonists or tumor cells. Indeed, sepsis is
associated with an increase in many circulating cytokines
and PAMPs (especially LPS). Previous reports showed
that the upregulation of CD69 is a sensitive marker in
neonatal sepsis [49] and reported the presence of circu-
lating CD56+CD69+ NK cells in sepsis [50].
For the first time, we explored TLR2, TLR4 and TLR9
expression on and in human blood NK cells during sep-
sis. First, our study revealed that NK cells from healthy
human donors mainly express TLR2 and TLR4 intracel-
lularly (the same expression pattern observed for TLR9).
The intracellular expression of TLR2 and TLR4 has
already been reported for other cells such as epithelial
[51], endothelial [52], or even dendritic cells [53]. These
intracellular TLRs are active, as reported by Hornef et
al. [54] who showed the possible activation of epithelial
cells after internalization of a TLR ligand. For NK cells,
only a low percentage of both subsets express surface
TLR2 and TLR4 at low density. A large part of the
knowledge on TLR expression in NK cells from both
human or mouse subjects has been acquired in studies
based on mRNA detection, and remains controversial
[22-24,39,40] However, mRNA detection is not equiva-
lent to protein expression, which depends on transla-
tional and post-translational events that will confer the
functionality and the right cellular localization. For this
reason, we chose to address TLR2 and TLR4 expression
in NK cells in terms of protein expression. We obtained
very similar results with mouse spleen NK cells [55],
suggesting that the intracellular expression of TLR2 and
TLR4 is a general feature of naive NK cells present in a
healthy environment. Our present study shows that this
expression can be modified in human SIRS and sepsis.
Most interestingly, the percentage of NK cells expressing
intracellular TLR2 was significantly increased in sepsis for
Figure 4 Expression of CD69 on natural killer (NK) cell CD56bright and CD56dim subsets on freshly isolated cells or after in vitro
cultures. (A) Representative flow cytometry histograms of surface basal expression of CD69 on CD56bright and CD56dim NK cell subsets for
healthy volunteers, systemic inflammatory response syndrome (SIRS), and sepsis patients. Black line: isotype control; colored line: anti-CD69. (B)
CD69 expression in all three groups for freshly isolated NK cells (basal) or after overnight culture in the presence of IL-15 + IL-18; data are shown
as median and interquartile range. CD69 expression expressed after overnight culture in the presence of IL-15 + IL-18 and lipopolysaccharide
(LPS) (C), CpG (D) and heat-killed S. aureus (HKSA) (E); data are expressed as median and interquartile range. *P < 0.05; **P < 0.01; ***P < 0.001
for comparison between healthy donors and patients. MFI, mean fluorescence intensity.
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the CD56dim subset. Similarly, the MFI of intracellular
TLR2 in CD56bright and CD56dim subsets was significantly
increased in sepsis patients compared to healthy controls.
For TLR4, an increase in the percentage of NK cells posi-
tive for surface expression was only observed in SIRS
patients. In contrast, intracellular TLR4 expression was
significantly enhanced in sepsis patients and SIRS patients
compared to healthy controls in both NK subsets. This is
the first report showing a modulation of TLR expression
in NK cells from ICU patients. To date, TLR2 and TLR4
expression has been mainly studied in monocytes, and
most studies show enhanced surface expression of TLR2
Figure 5 Flow cytometry analysis of IFN-g secretion in whole blood by CD56bright and CD56dim natural killer (NK) cell subsets after
overnight ex vivo stimulation. (A) IL-15 + IL-18; (B) IL-15 + IL-18 + LPS; (C) IL-15 + IL-18 + CpG-DNA; (D) IL-15 + IL-18 + heat-killed S. aureus
(HKSA). Median and interquartile range are shown for each group. *P < 0.05; ***P < 0.001 for comparison between healthy donors and patients.
MFI, mean fluorescence intensity.
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in sepsis, while the data concerning TLR2 surface expres-
sion in trauma and SIRS patients or TLR4 expression are
more controversial. It is still unclear which circulating
mediators are able to modulate the TLR expression in
NK cells. Nevertheless, it is of interest to note that the
percentage of positive cells for surface TLR4 expression
on NK cells allows discrimination of patients with sepsis
and SIRS.
As a measure of the functionality of NK cells circulat-
ing in the blood of ICU patients, we show that NK cells
undergo a dramatic alteration of their capacity to pro-
duce IFN-g when exposed in vitro to TLR4 or TLR9
agonists in the presence of the accessory cytokines IL-
15 and IL-18. This reduced production of IFN-g occurs
despite enhanced TLR4 expression in SIRS patients and
unchanged TLR9 intracellular expression in all groups.
The TLR2 agonist Pam3CysSK4 was tested on NK cells
from healthy controls and on those from a few patients.
Because in both cases the responsiveness was very low,
we no longer used this TLR2 agonist in this study. In a
similar fashion observed for NK cell response to purified
PAMPs, the response to whole bacteria (HKSA) was
profoundly altered. Although, altered IFN-g production
in response to LPS has already been reported in whole
blood samples from sepsis patients [56], this is the first
direct demonstration that IFN-g production by NK cell
subsets is altered in human sepsis and SIRS. Neverthe-
less, we addressed circulating NK cells, and their altered
reactivity is not necessarily the reflection of that of their
counterparts present in the tissues. Access to cells from
compartments other than blood is much easier in ani-
mal models. In mice a decreased capacity of liver NK
cells to produce IFN-g in response to LPS has also been
reported [57], and in this murine model of sepsis, Scott
et al. hypothesized that IL-10 was responsible for the
suppressed production of IFN-g [58]. However, in a
mouse model of sepsis, analyzing spleen NK cells, we
recently showed that TGF-b, more than IL-10, was the
deactivating cytokine [55]. To our knowledge only one
group has performed studies with the human spleen.
Their study reports an altered response to LPS, but does
not address NK cell immune status [59]. Our results fit
with the alteration of the cytotoxic activity already
reported for NK cells from ICU patients. Indeed,
reduced cytotoxic activity has been regularly reported
for the past 25 years in patients with thermal injury
[34,35] and more recently observed in both adult and
newborn patients with sepsis [32,60]. Some reports also
demonstrate that in many patients NK cells are unre-
sponsive to IL-2 and IFN-a as assessed in terms of
cytotoxicity.
It is important to note that NK cells from healthy
donors need both signals, IL-15 and IL-18, and the pre-
sence of PAMPs, to produce IFN-g ex vivo. In our
experimental model, it is not yet possible to decipher
whether NK cells from patients fail to respond to the
cytokine cocktail (that is, IL-15 plus IL-18) used to favor
their response to PAMPs and whole bacteria, or fail to
respond to the microbial products themselves, or fail to
respond to both. However, cytokines alone were able to
upregulate the expression of CD69 in NK cells from
SIRS and sepsis patients. Of note, in the presence of
PAMPs or HKSA, NK cells from healthy controls
showed an additional increase in CD69 expression ex
vivo in terms of MFI. In almost all cases the expression
of CD69 on NK cells from patients remained signifi-
cantly lower than levels observed for healthy controls,
suggesting that their NK cells are somehow refractory to
CD69 upregulation by bacterial products ex vivo. This
may suggest that the deficit in NK cell responsiveness
for patients mainly occurs during the reaction to micro-
bial agonists. We cannot exclude a role of accessory
cells in whole blood via IL-12 production in the hypore-
sponsiveness observed for NK cells. However, we
recently showed in a mouse model that purified NK
cells are responsive to TLR agonists in the presence of
IL-15/IL-18 and that they become tolerant to this ex
vivo challenge following polymicrobial sepsis [55], which
is in favor of a deactivation of NK cells themselves.
In animal models, including the injection of LPS, ther-
mal injury, surgery or sepsis, altered cytotoxic activity has
also been reported [61-63]. In these models, spleen NK
cells or NK cells from other compartments, such as the
lungs, also displayed a reduced capacity to produce IFN-g
[64]. It is worth mentioning that none of these murine
models have addressed circulating NK cells, which are
those studied in humans. This difference may explain
why sometimes some discrepancies are found in the roles
of NK cells in animal models of sepsis. Depending on the
experimental model, NK cells have been reported to be
beneficial or deleterious in fighting polymicrobial sepsis
in the cecal ligation and puncture murine model. Among
the factors that can contribute to NK cell dysfunction,
altered macrophage accessory activity [25] and an immu-
nosuppressive action of IL-10 [64], TGF-b and regulatory
T cells (Tregs) [55] have been suggested. In addition, it is
also possible that apoptosis, which may occur in surgery
patients, and seems to take place also during sepsis, [59]
contributes to alterations in NK cell functions. Indeed,
IL-15 treatment of infected mice was shown to prevent
NK cell apoptosis, and in cases of polymicrobial sepsis
and pneumonia, treatment was associated with improved
survival [65]. This observation suggests that NK cells
with an appropriate immune status would be beneficial
to counter the severe infectious processes observed in
sepsis. This is also congruent with reports suggesting an
association between low NK cell counts and poor patient
outcome [48].
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Conclusions
In this study, we further extended the concept of CARS
to human NK cells for both CD56bright and CD56dim
subsets. We demonstrated a defect of NK cells for both
CD69 upregulation and IFN-g production ex vivo in
response to accessory cytokines and PAMPs, or acces-
sory cytokines and whole bacteria in sepsis and SIRS
patients. Finally, we determined that expression of TLR2
and TLR4 is mostly intracellular in circulating human
NK cells and that these receptors are upregulated differ-
entially in and on NK cells of SIRS and sepsis patients,
allowing discrimination of these two groups of patients.
Key messages
• TLR2 and TLR4 are mainly expressed intracellu-
larly in NK cells.
• Intracellular expression of TLR2 and TLR4 in both
CD56Dim and CD56Bright NK cell subsets is enhanced
during sepsis.
• CD69 expression is enhanced on NK cells from
SIRS and sepsis patients but may still be futher
increased by the addition of IL-15 plus IL18.
• Production of IFN-g by circulating NK cells is
altered in SIRS and sepsis patients.
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unstimulated cells; colored line: IFN-g positive cells.
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